Regeneration of the Immune System after Radiation Exposure

辐射暴露后免疫系统的再生

基本信息

  • 批准号:
    10474871
  • 负责人:
  • 金额:
    $ 58.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-18 至 2027-06-30
  • 项目状态:
    未结题

项目摘要

Abstract Radiation-Induced Immune Dysfunction (RIID) is a critical component of both acute and delayed effects of radiation exposure, which causes a multi-organ failure (MOF) syndrome, operationally divided based upon timing of clinical manifestations, as acute radiation syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). The immediate lethality of ARS is caused by bone marrow and intestinal failure, with subsequent neutropenia, anemia, thrombocytopenia, lymphopenia, and loss of intestinal epithelial barrier, resulting in bacteremia, septic shock, and systemic inflammatory response. To date, FDA-approved radiation countermeasures are hematopoietic growth factors, such as, G-CSF, GM-CSF and Romiplostim that promote myeloid regeneration in the marrow. Ionizing radiation (IR) can cause reversible and irreversible damage to the immune system. Atomic bomb (A-bomb) survivors from Japan exhibited reduction in T helper cell subsets, alterations in naïve and memory T and B lymphocyte numbers and function, increased levels of serum pro- inflammatory cytokines, indicating significant residual injury and impairment of lymphocyte homeostasis in the lymphoid organs. We will investigate the immune landscape of regeneration in bone marrow, peripheral lymphoid organs (spleen, thymus, and peritoneal lymph nodes) and mucosa-associated lymphoid tissue (MALT) of the intestine and lungs, determine the functionality of antigen presenting cells, and whether IR induces mitochondrial dysfunction, inhibits macro- and chaperone-mediated autophagy, and accelerates T cell immunosenescence and inflammation following WBI under aim 1. We will also examine the regeneration of immune effector cells for mitochondrial dysfunction, inhibition of autophagy, accelerated immunosenescence, T cell exhaustion and inflammation in lymphocytes from peripheral lymphoid organs in mice exposed to IR and treated with radio-mitigators, TPOm or Flt3L or G-CSF (as control), 1-day post-WBI in aim 2. Under aim 3 we will develop an immuno-conditioning regimen to restore functional immune deficit for immunization protocols in radiation survivors, treated with or without radio-mitigators. We will also examine the effects of metformin and p38/MAPK inhibitor to overcome T cell immunosenescence as conditioning regimens with immunological outcomes measured by antigen-specific IgM, IgG and Th1 and Th2 responses. Relevance. Our proposal will define the functional radio-immunobiology of the regenerative immune system after WBI in mice. Since the tissue targets of radiation injury are well studied, we can also correlate whether T cell immunosenescence and dysfunction of myeloid population contributes to DEARE. These studies will provide a blueprint for developing optimized immuno-conditioning regimens for immunization protocols in radiation survivors that can be extended to immunocompromised and elderly population.
摘要 辐射诱导的免疫功能障碍(RIID)是辐射的急性和延迟效应的关键组成部分。 辐射暴露,导致多器官衰竭(MOF)综合征,根据时间进行操作划分 临床表现,如急性辐射综合征(ARS)和急性辐射照射的延迟效应 (亲爱的)。ARS的直接致死性是由骨髓和肠衰竭引起的,随后 中性粒细胞减少、贫血、血小板减少、淋巴细胞减少和肠上皮屏障丧失,导致 菌血症、败血性休克和全身炎症反应。到目前为止,FDA批准的辐射 对抗措施是造血生长因子,如G-CSF、GM-CSF和罗米司亭,其促进 骨髓中的骨髓再生电离辐射(IR)可对人体造成可逆和不可逆的损伤。 免疫系统来自日本的原子弹(A-炸弹)幸存者表现出T辅助细胞亚群的减少, 幼稚和记忆性T和B淋巴细胞数量和功能的改变,血清pro- 炎性细胞因子,表明显著的残留损伤和淋巴细胞稳态的损害, 淋巴器官 我们将研究骨髓、外周淋巴器官(脾, 胸腺和腹膜淋巴结)和肠和肺的粘膜相关淋巴组织(MALT), 确定抗原呈递细胞的功能,以及IR是否诱导线粒体功能障碍,抑制 巨噬细胞和分子伴侣介导的自噬,并加速T细胞免疫衰老和炎症 在目标1下遵循世界银行倡议。我们还将研究线粒体免疫效应细胞的再生, 功能障碍,抑制自噬,加速免疫衰老,T细胞耗竭和炎症, 暴露于IR并用放射缓解剂TPOm或 Flt 3L或G-CSF(作为对照),目标2中WBI后1天。根据目标3,我们将开发一种免疫调节 用于恢复放射幸存者的免疫方案的功能性免疫缺陷的方案, 没有无线电衰减器我们还将研究二甲双胍和p38/MAPK抑制剂对克服T 细胞免疫衰老作为预处理方案,通过抗原特异性 IgM、IgG和Th 1和Th 2应答。 本案无关我们的建议将定义再生免疫系统的功能性放射免疫生物学 在小鼠WBI后。由于对辐射损伤的组织靶点进行了充分的研究,我们也可以将T 细胞免疫衰老和髓细胞群功能障碍有助于DEARE。这些研究将提供 为辐射免疫规程制定最佳免疫调节方案的蓝图 幸存者可以扩展到免疫功能低下和老年人群。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chandan Guha其他文献

Chandan Guha的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chandan Guha', 18)}}的其他基金

Understanding stem cell heterogeneity and niche function in intestinal regeneration after irradiation
了解辐射后肠道再生中的干细胞异质性和生态位功能
  • 批准号:
    10910625
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
Regeneration of the Immune System after Radiation Exposure
辐射暴露后免疫系统的再生
  • 批准号:
    10686385
  • 财政年份:
    2022
  • 资助金额:
    $ 58.23万
  • 项目类别:
Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
碳离子放射治疗胰腺癌的相对免疫有效性(RIE)
  • 批准号:
    10158123
  • 财政年份:
    2021
  • 资助金额:
    $ 58.23万
  • 项目类别:
Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
碳离子放射治疗胰腺癌的相对免疫有效性(RIE)
  • 批准号:
    10330035
  • 财政年份:
    2021
  • 资助金额:
    $ 58.23万
  • 项目类别:
Relative Immunological Effectiveness (RIE) of Carbon Ion Radiation Therapy for Pancreatic Cancer
碳离子放射治疗胰腺癌的相对免疫有效性(RIE)
  • 批准号:
    10544737
  • 财政年份:
    2021
  • 资助金额:
    $ 58.23万
  • 项目类别:
Stromal cell therapy as a treatment against Gastrointestinal Acute Radiation Syndrome (GI-ARS)
基质细胞疗法作为胃肠道急性放射综合症(GI-ARS)的治疗方法
  • 批准号:
    9886178
  • 财政年份:
    2018
  • 资助金额:
    $ 58.23万
  • 项目类别:
Stromal cell therapy as a treatment against Gastrointestinal Acute Radiation Syndrome (GI-ARS)
基质细胞疗法作为胃肠道急性放射综合症(GI-ARS)的治疗方法
  • 批准号:
    10359772
  • 财政年份:
    2018
  • 资助金额:
    $ 58.23万
  • 项目类别:
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
使用聚焦超声增加黑色素瘤免疫原性并抑制肿瘤诱导的 T 细胞耐受
  • 批准号:
    10365967
  • 财政年份:
    2018
  • 资助金额:
    $ 58.23万
  • 项目类别:
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
使用聚焦超声增加黑色素瘤免疫原性并抑制肿瘤诱导的 T 细胞耐受
  • 批准号:
    9893711
  • 财政年份:
    2018
  • 资助金额:
    $ 58.23万
  • 项目类别:
Immune modulation of radiation therapy with Flt3 ligand
Flt3配体对放射治疗的免疫调节
  • 批准号:
    9129622
  • 财政年份:
    2015
  • 资助金额:
    $ 58.23万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 58.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 58.23万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 58.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了